Enfuvirtide Production Cost Reports

The report provides a detailed analysis essential for establishing an Enfuvirtide production plant. It encompasses all critical aspects necessary for Enfuvirtide production, including the cost of Enfuvirtide production, Enfuvirtide plant cost, Enfuvirtide production costs, and the overall Enfuvirtide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Enfuvirtide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Enfuvirtide is a synthetic peptide drug used for the treatment of HIV-1 infections. It is primarily used in combination with other antiretroviral agents, particularly in treatment-experienced patients with HIV-1 replication despite ongoing antiretroviral therapy. It is prescribed for patients with HIV who do not respond well to other antiretroviral medicines. The drug works by blocking the virus from entering healthy immune cells, which helps reduce the spread of the virus in the body. It is administered by subcutaneous injection and supports better control of viral load in advanced cases of HIV. Moreover, is also sometimes studied in experimental settings for its potential in preventing viral entry in other enveloped viruses.

The demand for Enfuvirtide is primarily driven by its application in long-term HIV management and slow disease progression when other treatment options are limited, which boosts its market expansion. Its application as a part of combination antiretroviral therapy for individuals with advanced HIV infection significantly drives its demand in the pharmaceutical industry. Its application as an antiretroviral drug in the treatment of HIV-1 infection, particularly in patients who have not responded well to standard therapies, further boosts its demand in the medical sector.

Its demand as an important drug in salvage therapy for patients with drug-resistant cases of HIV also contributes to its market growth. Additionally, industrial Enfuvirtide procurement is affected by factors such as the high cost and complexity of peptide synthesis, availability of specialised raw materials, and adherence to strict regulatory guidelines. Technological advancements in peptide production, improved delivery systems, supplier dependability, and global distribution capabilities further shape its procurement decisions.

Raw Material for Enfuvirtide Production

According to the Enfuvirtide production plant project report, the major raw materials for Enfuvirtide production include Fmoc-protected amino acids and 2-Chlorotrityl Chloride Resin.

Production Process of Enfuvirtide

The extensive Enfuvirtide production cost report consists of the following industrial production process:

1. Production via Solution-Phase and Solid-Phase Methods: The production process of Enfuvirtide begins with the chemical synthesis of short peptides using a combination of solution-phase and solid-phase methods. In the solid-phase steps, Fmoc-protected amino acids are sequentially coupled on a 2-chlorotrityl chloride resin. The resin is sensitive to acid, and it allows efficient elongation of peptide chains ranging from nine to sixteen amino acids. After assembling the full-length sequence through repeated coupling and deprotection cycles, side-chain protecting groups are removed. Then, the crude peptide is cleaved from the resin and purified using column chromatography to obtain Enfuvirtide as the final product.

Enfuvirtide is a synthetic peptide fusion inhibitor used for the treatment of HIV-1 infection. It appears as a white to off-white amorphous solid powder. The molecular formula of the compound is C204H301N51O64, and its molecular weight is 4492 g/mol. The compound has a density of approximately 1.59 g/cm³ and is a 36-amino acid peptide. It has negligible solubility in pure water, but solubility increases in aqueous buffers at pH 7.5 to reach 85 to 142 g per 100 mL. The compound must be administered via subcutaneous injection as it cannot be taken orally due to its peptide nature. Nearly all patients experience injection site reactions, including pain, hardening of skin, erythema, nodules, cysts, and pruritus, particularly during the first week of treatment. Extended exposure to this medication may cause serious health problems, including bacterial pneumonia, peripheral neuropathy, hypersensitivity reactions, immune reconstitution syndrome, eosinophilia, and, in rare cases, Guillain-Barré syndrome.